Aerogen Ltd

Aerogen Ltd specializes in nebulizers, which are devices used to deliver aerosolized medication directly to the lungs. Their portfolio includes portable and hospital-grade systems, such as the Aerogen Ultra and Solo series, designed for both pediatric and adult patients. These devices range from compact single-use nebulizers to reusable systems, continuous nebulization tube sets, and controller systems like the Aerogen Pro-X1 and USB Controller. The focus is on aerosol delivery for respiratory therapies.

Aerogen Ltd is headquartered in Ireland. Their devices are authorized in both the European Union and the United States, as evidenced by their listings in the EUDAMED database (for EU regulatory compliance) and the FDA’s 510(k) premarket notification registry (for U.S. clearance). This indicates their products meet the regulatory requirements for medical devices in these markets.

Aerogen’s devices fall under Class II, Class IIa, and Class IIb classifications according to the EU Medical Device Regulations. This classification is determined by factors like the risk associated with the device’s use, its intended purpose, and potential patient exposure. Class II devices typically involve moderate risks and require additional scrutiny, such as clinical evaluations or specific manufacturing controls, to ensure safety and performance.

Aerogen’s devices are listed in two key regulatory registries: EUDAMED, the European database for medical devices, which tracks authorized products under EU regulations, and the FDA’s 510(k) premarket notification registry, which documents U.S. medical devices that have received clearance through the 510(k) process. These listings confirm their compliance with respective market requirements.

Aerogen’s nebulizers are designed with a focus on efficiency, portability, and specialized applications. For example, their Solo series includes pediatric-specific masks and T-piece adapters, while the Pro-X1 Controller System enables automated therapy. The company also offers continuous nebulization tube sets for extended treatment durations, catering to both acute care and home-use scenarios. Their classification as Class II/IIa/IIb reflects a balance between performance and risk, ensuring they meet stringent regulatory standards for aerosolized medication delivery.